Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Shares Outstanding (Diluted Average) (2019 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $26.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 49.63% to $26.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.0 million through Dec 2025, up 49.63% year-over-year, with the annual reading at $26.0 million for FY2025, 49.63% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $26.0 million at Cartesian Therapeutics, roughly flat from $26.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $148.5 million in Q2 2022, with the low at $5.1 million in Q1 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $60.0 million, with a median of $26.0 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Diluted Average) plummeted 96.56% in 2023, then skyrocketed 378.44% in 2025.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $114.3 million in 2021, then rose by 27.59% to $145.9 million in 2022, then crashed by 96.46% to $5.2 million in 2023, then soared by 235.72% to $17.4 million in 2024, then skyrocketed by 49.63% to $26.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $26.0 million, $26.0 million, and $26.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.